Bing Li

In a single sweep, the machine Bing Li helped build captures 130 degrees of the living retina, reaches twelve millimeters into tissue, and finishes the math in about twenty seconds. That is the pitch in numbers. The pitch in plain language is simpler: clinicians kept asking for an imaging tool that did not make them choose between speed, depth, and field of view. Li's company set out to refuse the trade-off.

Li is the CEO and co-founder of Intalight, an ophthalmic technology company started in 2014 by a group of scientists and Silicon Valley industry veterans. Its flagship is the DREAM OCT platform - a swept-source optical coherence tomography system. OCT is, roughly, ultrasound made of light: instead of sound waves bouncing back from tissue, it uses near-infrared light to build cross-sections of the retina layer by layer. Swept-source is the newer, faster flavor of the technique, and Intalight shipped one of the first such devices in 2019.

What makes the origin worth telling is where Li came from before he came to eyes. His training is in engineering and applied mathematics, not medicine. He earned a bachelor's degree from Kettering University - the cooperative engineering school in Flint, Michigan, that grew out of General Motors - then a master's in applied mathematics from Purdue, and later a graduate certificate in systems engineering from Stanford. His early career ran through the industrial machine of America: a stint as a regional engineering manager at General Motors, and roles connected to the semiconductor-inspection giant KLA-Tencor. Cars and chips. Then the retina.

That lineage is not a footnote. The hard problems in OCT are not really medical problems; they are problems of optics, signal processing, and motion. An eye moves. A patient blinks. A cloudy lens scatters light before it ever reaches the retina. Building a machine that captures a clean, ultra-wide, deep image in a fraction of a second is an engineering and mathematics problem dressed in a clinical coat. Li had spent two decades on exactly that kind of problem in other industries.

Intalight's geography tells its own story. Founded in Silicon Valley, the company moved its base of operations to mainland China in 2015 and now runs across three sites - Silicon Valley, Shanghai, and Luoyang. That spread is part design choice and part necessity: the optical research and the manufacturing scale that medical hardware demands rarely live in the same zip code. Running a device company across that distance, and across time zones, is its own quiet feat of operations.

The "imaging finish line"

Li likes the phrase "imaging finish line." It captures a frustration ophthalmologists know well. A retina specialist might want an ultra-widefield map of the blood vessels, a deep look at the choroid beneath the retina, and a clean read through a patient whose lens has clouded with age - and traditionally needed different settings, or different machines, to get each one. DREAM OCT is the attempt to collapse those errands into one device and, ideally, one scan.

The name is an acronym, and an unusually honest one. DREAM stands for Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging. Each letter is a specification the team chose to compete on rather than a marketing flourish. The device can deliver a 130-degree OCT-angiography image in a single ultra-widefield scan, push twelve millimeters deep for choroid and retina, and capture the anterior segment - cornea through the front of the vitreous - across a 16.2mm range in air.

Speed is the unsung hero. DREAM runs at scan rates from 200 to 400 KHz, and that velocity matters for a reason patients feel: the faster the capture, the fewer artifacts from eye movement smear the result. A high-resolution angiogram of the retina's smallest vessels is only useful if the eye holds still, and the surest way to make an eye hold still is to finish before it has time to wander.

Proof by publication

There is a tell for whether a research instrument is any good: do scientists actually use it to publish? By Intalight's count, more than 170 peer-reviewed papers have drawn on findings from DREAM OCT devices. That body of work spans retinal disease, choroidal vessel analysis, myopia research, and tumor-vessel imaging - the kind of varied citation list that suggests researchers reach for the machine because it answers questions other tools cannot, not because a sales rep left one in the lab.

For a long stretch, this was a story told mostly outside the West. The validation came; the regulatory checkmarks for the largest markets did not, yet. That changed in stages. In June 2024, Intalight announced DREAM OCT approval in Brazil. Then, in May 2025, the company received the CE Mark - the certification that clears a medical device for sale across the European Union. It was the moment a research-respected platform became a commercial product on one of the world's most demanding regulatory stages. In the United States, FDA review remains pending.

It is worth sitting with what the CE Mark means for a company like this. Winning it is not a press-release formality; it is a multi-year exercise in documentation, clinical evidence, quality systems, and audits. For a startup that built its reputation on the research bench, it is the bridge from "the scientists trust it" to "the regulators will let you sell it." Li's team crossed that bridge in 2025.

The quieter mission

Intalight's stated mission is to develop the most advanced ophthalmic technologies, and its tagline - "Light Every Sight" - is the rare slogan that is also a literal description of the product. OCT is, at bottom, a way of using light to see what the eye cannot show on its own. There is a neatness to an applied mathematician spending his second act on the geometry of light inside the human eye.

What is striking about Li's public posture is how little of it is about Li. The quotes are about clinicians and their problems. The product name is a checklist of engineering promises. The company talks about peer-reviewed papers and scan ranges rather than founder mythology. In an industry that loves a visionary narrative, Intalight's pitch is closer to a spec sheet that happened to win over the people who use it. For an engineer who came up through GM and the chip world, that may be exactly the point.